A pilot study of concurrent whole-brain radiotherapy and chemotherapy combined with cisplatin, vindesine and mitomycin in non-small-cell lung cancer with brain metastasis
1997

Study on Whole-Brain Radiotherapy and Chemotherapy for Lung Cancer with Brain Metastasis

Sample size: 33 publication Evidence: moderate

Author Information

Author(s): K Furuse, T Kamimori, M Kawahara, N Kodama, M Ogawara, S Atagi, N Naka, M Akira, K Kubota

Primary Institution: National Kinki Central Hospital for Chest Diseases, Osaka, Japan

Hypothesis

Can concurrent whole-brain radiotherapy and chemotherapy improve outcomes for patients with non-small-cell lung cancer and brain metastasis?

Conclusion

The study found that concurrent whole-brain radiotherapy and chemotherapy can be safely administered, resulting in a significant response rate and improved survival duration.

Supporting Evidence

  • 75.8% of patients responded to brain lesions, including five complete responders.
  • 30% of patients improved at least one grade of performance status.
  • Median survival was 9.7 months with a 1-year survival rate of 40%.

Takeaway

Doctors combined radiation and chemotherapy to help patients with lung cancer that spread to the brain, and many patients got better and lived longer.

Methodology

Patients received a combination of whole-brain radiotherapy and chemotherapy with cisplatin, vindesine, and mitomycin, and their responses were evaluated over time.

Potential Biases

Potential bias due to the uncontrolled nature of the study and patient selection.

Limitations

The study was uncontrolled and had a bias for patient selection.

Participant Demographics

Patients had non-small-cell lung cancer with brain metastasis, aged less than 75 years.

Statistical Information

P-Value

0.0288

Confidence Interval

57.74-88.90%

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication